ADMA Biologics, Inc. reported its financial performance for the third quarter of 2025 on January 13th. The company's share was trading at $17.70 on that date.
Revenue for the quarter reached $134.2 million, representing a 12% increase compared to the same period last year. Over the trailing twelve months, revenue rose nearly 28% to $488.6 million.
Profitability expanded significantly during this period. Trailing twelve-month earnings per share increased by more than 200%. Gross margins remained above 54%.
ADMA Biologics specializes in plasma-derived immunoglobulin therapies for patients with immune deficiencies. The company operates a fully vertically integrated model that spans from plasma collection through manufacturing.
Management has raised its full-year 2025 revenue guidance to at least $510 million. The company has indicated a clear path toward $630 million in revenue for 2026 and over $1.1 billion by 2029.
A key development mentioned was FDA approval of yield-enhanced production methods. This approval is expected to increase output per unit of plasma and could drive gross margin expansion toward 70% beginning in 2026.
The company also has a preclinical hyperimmune globulin candidate in its pipeline. This candidate could potentially generate significant high-margin revenue in the future.
According to Yahoo Finance data, ADMA's trailing price-to-earnings ratio was 20.58, while its forward price-to-earnings ratio stood at 28.99.
At the end of the third quarter, 42 hedge fund portfolios held positions in ADMA Biologics. This represented an increase from 33 hedge fund holdings in the previous quarter.